EU Legislative Review Needs To ‘Fix The Ecosystem’ For ATMPs
Executive Summary
Developers of advanced therapies say the European Commission must do more to address the “hospital exemption” and the regulation of advanced therapy medicinal products as genetically modified organisms.
You may also be interested in...
Expanding Hospital Exemptions For ATMPs Could Make Europe Less Attractive To Investors
The forthcoming overhaul of the EU pharma legislation should not include an expansion of the hospital exemption provision for advanced therapies, warn industry and regulators.
Industry Bodies Urge GMO Exemption For Advanced Therapies In EU
ATMPs should be treated like COVID-19 products when it comes to the EU rules on genetically modified organisms, say ARM, EFPIA and EuropaBio.
EU Review Proposals ‘Fail To Analyze’ Impact Of Reduced Exclusivity Periods
Plans for the overhaul of the EU’s medicines framework are missing key analysis on the effect of reductions in data and market protection on the pharmaceutical industry, despite an abundance of studies on how such incentives influence company decisions on whether to develop new products, say lawyers from Sidley.